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Abstract: Following the successful development of long-acting steroid-releasing vaginal ring 
devices for the treatment of menopausal symptoms and contraception, there is now consider-
able interest in applying similar devices to the controlled release of microbicides against HIV. 
In this review article, the vaginal ring concept is first considered within the wider context of 
the early advances in controlled-release technology, before describing the various types of ring 
device available today. The remainder of the article highlights the key developments in HIV 
microbicide-releasing vaginal rings, with a particular focus on the dapivirine ring that is pres-
ently in late-stage clinical testing.
Keywords: controlled release, sustained release, antiretroviral, dapivirine, SILCS diaphragm, 
silicone elastomer, thermoplastic
Introduction to controlled drug release  
and vaginal rings
The concept of controlled drug release from polymeric materials was first established in 
the 1960s by Judah Folkman when he discovered that exposure of anesthetic gases to the 
external surface of a silicone rubber arteriovenous shunt containing circulating rabbit blood 
caused the rabbits to fall asleep.1 Based on this ability of gaseous molecules to permeate 
silicone rubber, it was postulated that solid drugs incorporated into silicone rubber (or 
other elastomeric polymers) could be implanted in the body to provide rate-controlled 
drug-delivery systems.2,3 The first controlled-release drug-delivery systems to be com-
mercialized were two devices: Alza’s Ocusert® (an ophthalmic insert releasing pilocarpine 
at a constant rate for the treatment of glaucoma) and Progestasert® (an intrauterine implant 
providing a constant rate of progesterone delivery). Both were reservoir-type devices fab-
ricated from the thermoplastic polymer poly(ethylene-co-vinyl acetate) (PEVA). The first 
commercial silicone elastomer device for controlled release was the Population Council’s 
subdermal contraceptive implant Norplant®, first approved for use in Finland in 1983 and 
marketed in the USA in 1991. Consisting of six small (2.4 mm × 34 mm) silicone elastomer 
cylinders, each filled internally with 36 mg of levonorgestrel (a progestin used in many 
birth-control pills), Norplant® was a direct extension of Folkman’s original concept and 
provided effective fertility control for five years. A second generation of Norplant®-type 
devices is currently available, containing either one or two drug-loaded rods and fabricated 
from either silicone elastomer or PEVA.
In 1970, a US patent assigned to the UpJohn Company was published describing 
“an improved resilient annular device for intravaginal placement and retention . . . 
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containing an effective amount of a medicament which is 
capable of passage through the drug-permeable polymeric 
material” (Figure 1A).4 This first description of the concept 
of a drug-releasing vaginal ring heralded an intense period 
of activity in ring development through the 1970s and 1980s, 
mainly focused around contraception and hormone replace-
ment therapy and involving various ring designs. The World 
Health Organization (WHO) was at the forefront of this 
research with their program for the development of a sili-
cone elastomer steroidal contraceptive ring to help contain 
the burgeoning population growth. The interested reader is 
directed to Hoffman’s excellent overview on the origins and 
evolution of controlled-release drug-delivery systems.5
Vaginal rings
Vaginal rings are flexible, torus-shaped, silicone elastomer 
or thermoplastic devices that provide long-term, sustained 
or controlled delivery of pharmaceutical substances to the 
vagina for either local or systemic effect. Designed to be 
readily inserted and removed by the woman herself, they are 
generally positioned in the upper third of the vagina adjacent 
to the cervix. Although the exact location of ring placement 
is generally not critical for clinical efficacy, it may have 
implications for comfort in some women.
The simplest vaginal ring design contains solid drug 
particles (usually in a micronized form) dispersed through-
out the entire polymeric matrix. The drug-release yield 
from these so-called “homogeneous” or “matrix” rings 
 (Figure 1B) is governed by a permeation mechanism for 
which the release rate is dependent upon (1) the drug’s solu-
bility in the polymer, (2) the ability of the solvated drug to 
diffuse through the  polymer, (3) the drug-loading within the 
device, and (4) the ring surface area. The drug-permeation 
process involves dissolution of the solid drug in the polymer, 
followed by diffusion of the solubilized molecules through 
the elastomeric polymer network. Drug near the surface of 
a matrix ring is released first, creating a drug-depleted layer 
through which solubilized molecules within the ring body 
must first diffuse in order to be effectively released. As time 
progresses the surface area of this inward-moving depletion 
boundary decreases, causing an increase in the thickness 
of the depletion layer, resulting in decreased drug-release 
rates over time.
The “sandwich” and “core” vaginal ring designs (also 
known as “shell” and “reservoir,” respectively) were devel-
oped to provide constant daily release rates throughout the 
period of use, conforming to “zero order” release kinetics. 
The sandwich design (Figure 1F) consists of a narrow drug-
loaded polymer layer positioned between a nonmedicated 
inner central core and a nonmedicated outer membrane. 
The position of the drug core close to the surface ensures 
efficient delivery of drugs having poor polymer diffusion 
characteristics. Core-type rings contain the drug(s) within 
one or more central cores that are encapsulated by a drug-free 
outer polymer membrane (Figure 1C–E). Several individual 
drug-loaded cores of various lengths may be incorporated 
into the same core ring, thereby allowing delivery of multiple 
actives at predetermined and independent release rates. The 
release rates of both the core and sandwich-ring designs 
may be further modified by changing the thickness of the 
rate-controlling outer membrane.
The range of materials used in the manufacture of vaginal 
rings is limited by the requirements for biocompatibility, 
flexibility, and high drug permeability. Commercial ring 
products are made from either silicone (polydimethylsi-
loxane) elastomer or PEVA. More recently, thermoplastic 
polyurethane materials have also being investigated for ring 
fabrication.6–9
Figure 1 Representative vaginal ring designs. (A) Over-molded metal spring design 
first described in a 1970 patent.4 (B) Matrix-type ring with solid micronized drug 
dispersed throughout the entire polymer. (C) Full length reservoir/core ring design, 
where the drug-loaded core is encapsulated by a nonmedicated, rate-controlling 
polymer membrane. (D) Multiple partial core ring design, where each core contains 
a different drug substance. (E) Insertable core ring design, where drug-loaded cores 
are inserted into a prefabricated ring body before sealing the ends. (F) Sandwich or 
shell ring design, where a drug-loaded layer is sandwiched between a nonmedicated 
polymeric central core and a nonmedicated outer rate-controlling polymer 
membrane.
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Silicone elastomer vaginal rings
Silicones represent a category of synthetic polymers compris-
ing a main chain of alternating silicon and oxygen atoms, and 
having two organic groups covalently bonded to the silicon 
atom (Figure 2).10 The most common silicone derivative is 
that having two methyl groups, called  polydimethylsiloxane. 
The linear polymeric forms of silicones are liquids at room 
temperature, even for large molecular weights. Elastomeric 
silicone materials are produced by incorporating reactive 
functional groups into the linear polymers that may be sub-
sequently “cross-linked” using suitable cross-linking mol-
ecules.  Silicone polymers, and particularly the elastomeric 
forms, have a long history of use in both medical devices 
and drug-delivery devices, stemming from their excellent 
biocompatibility and biodurability.11 Silicone elastomer 
rings are generally made by elevated-temperature reaction 
injection molding, using either condensation or addition-cure 
chemistries.10
Two estrogen-releasing, reservoir-type silicone elastomer 
vaginal rings have been commercialized for the treatment 
of menopausal symptoms related to estrogen deficiency. 
Estring® (Pfizer, New York, NY) contains a full-length 
reservoir core (Figure 1C) and releases 7.5 µg/day of 
17β-estradiol continuously over 3 months for the treatment of 
local symptoms. Femring® (Warner Chilcott UK Ltd, Larne, 
Northern Ireland) contains a single partial-length reservoir 
core (single-core version of Figure 1D) and releases either 
50 µg/day or 100 µg/day (depending on core length) of the 
estradiol  prodrug 17β-estradiol-3-acetate over 3 months for 
the treatment of both systemic and local symptoms. Both 
rings show a high degree of user acceptability and are pre-
ferred by women over estrogen vaginal gels.12–15 A 1-year 
combination contraceptive ring device, worn for 3 weeks 
per cycle and simultaneously releasing 15 mcg/day ethinyl 
estradiol and 150 mcg/day nestorone, is also in clinical 
development.16–19
The first report of a microbicide-releasing vaginal ring 
described the continuous in vitro release over 8 days of the 
non-ionic surfactant nonoxynol-9 from a matrix-type silicone 
elastomer device.20 Unlike the solid antiretroviral compounds 
currently being tested as HIV microbicides, nonoxynol-9 is 
a liquid at a room temperature, such that its release from the 
ring followed unconventional release kinetics. Nonoxynol-9 
has since been discontinued as a microbicide candidate since 
studies showed that it increased the risk of HIV transmis-
sion following frequent application.21,22 A subsequent study 
showed that dapivirine (also known as TMC120) could be 
effectively released in vitro over 71 days from a silicone 
elastomer reservoir-type ring device.23 Moreover, it was 
calculated that the constant daily rate observed of 130 µg 
release could effectively be maintained for at least 1 year, 
and theoretically for up to 4 years.
Many of the lead-candidate antiretroviral compounds 
being developed as HIV microbicides (eg, dapivirine, maravi-
roc, UC781, and MC1220) have physicochemical properties 
(specifically, high hydropobicity and low molecular weight) 
very similar to those of steroid molecules, suggesting that 
silicone elastomer vaginal ring formulations may also be 
A  Poly(dimethylsiloxane) pdms
B  Representative polyurethane structure
In the elastomeric form of this polymer,
the linear polymer chains are lightly crosslinked
to form a three-dimensional network 
Formed by the reaction of a polymeric diol
and an aromatic isocyanate
C  Poly(ethylene-co-vinyl acetate)
Properties determined by the molecular weight and
the fraction of vinyl acetate residues
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Figure 2 Chemical structures representing (A) silicone, (B) polyurethane and (C) poly(ethylene-co-vinyl acetate) materials used in the fabrication of drug-releasing vaginal 
rings.
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useful for the controlled release of microbicides. Although 
numerous antiretroviral compounds have been tested in rings 
in vitro, only the dapivirine-matrix and reservoir-type silicone 
elastomer rings have reached the clinical stages of develop-
ment (Table 1). Two Phase I safety studies have been com-
pleted for a 200 mg dapivirine reservoir ring (study IPM 001) 
(Figure 3A),24 a 25 mg dapivirine reservoir ring (studies IPM 
008 and IPM 01) (Figure 3B),24,25 and a 25 mg dapivirine 
matrix ring (study IPM 018) (Figure 3C).21 Although these 
rings had different designs, they were both manufactured 
using a condensation-cure silicone elastomer system spe-
cifically designed for the incorporation and release of drug 
molecules. The IPM 001 and IPM 008 studies demonstrated 
good safety and tolerability for both the 25 mg and 200 mg 
dapivirine reservoir-type rings, compared with a placebo 
ring, during the 7-day study period. Reported vaginal-fluid 
concentrations of dapivirine at various locations along the 
cervicovaginal tract (introitus, cervix, ring position) were in 
the range 0.7–7.1 µg/mL, with levels highest close to the 
ring and lowest at the introitus. Vaginal- and cervical-tissue 
concentrations on day 7 were between 0.3 µg/g and 3.5 µg/g. 
Plasma concentrations, which are a particularly important 
consideration from the perspective of the potential emergence 
of strains resistant to the drug in HIV-positive users, were 
less than 50 pg/mL. Dapivirine concentrations in vaginal fluid 
and tissue were more than three orders of magnitude greater 
than the in vitro EC50 against a wild-type HIV-1 strain.26,27 
Dapivirine levels measured with the 25 mg continuous core 
device (Figure 3B) were generally higher (but did not reach 
statistical significance) than those for the 200 mg two-core 
ring device (Figure 3A). This is consistent with the nature of 
membrane-type diffusion-controlled drug-delivery systems, 
where drug release kinetics are determined by the length of 
the reservoir and the thickness of the rate-controlling mem-
brane, but not the drug-loading (which only influences the 
duration of release).28
Reservoir rings are associated with several disadvantages 
compared with matrix-type rings, most notably their com-
plexity of manufacture (a multistep process) and the rela-
tively low (but constant) release rates. In the IPM 018 study 
(Table 1), the pharmacokinetics of matrix and reservoir 
rings, each containing 25 mg dapivirine (Figure 3B and C), 
were compared.25 The results clearly illustrated differences 
in dapivirine release rates, with significantly higher plasma 
100 mg DAP cores
A B
C D
25 mg DAP core
25 mg DAP matrix ring
7.6 mm 9.0 mm
55 mm56 mm
22 mm
3 mm 8.4 mm 7.6 mm
56 mm 56 mm
25 mg DAP core
IPM 001, Romano et al24
IPM 013, IPM 018, IPM 024, IPM 027,
MTN 020, Malcolm et al23, Nel et al25
IPM 008, IPM 018, Romano et al24,
Nel et al25
Malcolm et al23
Figure 3 Schematic diagrams (to scale) describing the design and dimensions of dapivirine-releasing vaginal rings. The design in (A) was evaluated in clinical study IPM 
001 (Table 1) and reported in Romano et al.24 The design in (B) was evaluated in IPM 008 and IPM 018 (Table 1), and reported in Romano et al24 and Nel et al.25 The 
design in (C) is the 25 mg dapivirine matrix ring due to progress to Phase III in 2012 as part of study MTN 020 (Table 1). It was previously tested in IPM 013, IPM 018, 
IPM 024, and IPM 027 (Table 1), and has been reported in Nel et al.25 The design in (D) is the reservoir-type dapivirine-releasing ring first reported in the literature by 
Malcolm et al.23
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Table 1 Completed, ongoing and planned microbicide ring clinical studies
Study Description Phase Countries Number women Status
IPM 001 Dapivirine ring safety I Belgium 12 Completed
IPM 008 Dapivirine ring safety I Belgium 13 Completed
IPM 011 Placebo ring safety and acceptability n/a South Africa/Tanzania 170 Completed
IPM 013 Dapivirine ring PK I Belgium 48 Completed
IPM 015 Dapivirine ring safety I/II Kenya, Malawi, South Africa, Tanzania 280 Data analysis
IPM 018 Dapivirine ring PK I Belgium 24 Completed
IPM 024 Dapivirine ring PK I Belgium 16 Completed
IPM 026/ 
MTN 013
Maraviroc, dapivirine, and  
dapivirine-maraviroc combination ring
I USA 48 Ongoing in 2012
IPM 027 Dapivirine ring long-term safety II South Africa, Rwanda, Kenya, Malawi 1650 Ongoing in 2012
MTN 020 Dapivirine ring efficacy and safety III Malawi, South Africa, Uganda,  
Zambia, Zimbabwe
3475 Ongoing in 2012
Notes: IPM refers to clinical studies completed or being undertaken by the International Partnership for Microbicides (Silver Spring, MD). MTN refers to studies being 
undertaken by the Microbicide Trails Network, a US National Institutes of Health-funded worldwide collaborative clinical trials network focused on preventing the sexual 
transmission of HIV.
Abbreviations: MRI, magnetic resonance imaging; PII, Phase II; C, control.
and vaginal-fluid levels achieved with the matrix format, 
owing to the presence and rapid release of the drug at 
the device surface (Figure 4). Vaginal-fluid levels peaked 
at ∼1000 µg/g 24 hours after placement of the matrix ring, 
and declined steadily to around ∼10 µg/g on day 28, imme-
diately prior to ring removal (Figure 4D). In general, vaginal-
fluid levels for the reservoir ring were between one and two 
orders of magnitude lower than those for the matrix ring. 
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Figure 4 Reported pharmacokinetic profiles for the 25 mg matrix and 25 mg reservoir rings tested in IPM 018. (A and B) show plasma concentrations (conc) over 24 hours 
and 33 days, respectively. (C and D) show vaginal-fluid concentrations over 24 hours and 33 days, respectively. 
Note: Rings were inserted at t = 0 and removed on day 28. 
© 2009 Lippincott Williams and Wilkins. Reprinted with permission. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and 
reservoir intravaginal rings to HIV-negative women.25
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Plasma levels of dapivirine ranged from 10–1000 pg/mL 
(Figure 4A and B).
The propanol by-product associated with condensation-
type silicone elastomers can lead to a “drug burst effect,” 
where the incorporated solid drug is dissolved in the pro-
panol, transported to the device surface, and subsequently 
deposited following evaporation of the propanol.29–31 This 
solvent-aided deposition of the drug can artificially increase 
its release rate during the early period of use, beyond that 
attributed to the normal polymer diffusion-controlled process. 
Subsequent studies have confirmed that a substantial drug 
burst occurred with the early prototype condensation-cure 
dapivirine-releasing silicone elastomer rings, prompting a 
move to addition-cure silicone elastomer systems (which 
produce no solvent by-product during the silicone-curing 
reaction) for the future clinical development of the dapivirine 
matrix ring. Preliminary pharmacokinetic data (unpublished) 
from the IPM013 and IPM024 Phase 1 studies for the 
addition-cure 25 mg-dapivirine ring showed detection of 
dapivirine in both vaginal fluid and plasma 1.5 hours after 
ring insertion; the maintenance of dapivirine concentra-
tions in vaginal fluid was in the 10–50 mcg/g range over the 
35-day study period. The ASPIRE Phase III study (MTN 
020, Table 1) of the addition-cure silicone elastomer 25 mg 
dapivirine ring will be launched at several African sites 
in 2012 and involve almost 3500 women. First results are 
anticipated in late 2014 or early 2015.
Following the success of antiretroviral combinations for 
the treatment of HIV infection, there is also considerable 
interest in combination microbicide products, including 
vaginal rings, that simultaneously release two or more micro-
bicide compounds having different mechanisms of action. 
The first clinical trial of such a ring (IPM 026/MTN 013, 
Table 1), comprising 25 mg dapivirine and 100 g maraviroc 
(an entry inhibitor) in an addition-cure silicone elastomer 
matrix format (Figure 1B) is planned for 2012 with 48 healthy 
women using either the combination ring, a 25 mg dapivirine-
only ring, a 100 mg maraviroc-only ring, or a placebo ring 
continuously for 28 days.
Microbicide-releasing silicone elastomer vaginal rings 
have also been designed for use in macaques, enabling impor-
tant pharmacokinetic and challenge studies to be performed 
in a more clinically relevant nonhuman-primate model.32–34
Thermoplastic vaginal rings
Thermoplastics are polymer substances that melt (and flow) 
upon heating and that harden again upon subsequent cooling. 
While most thermoplastic materials are not suitable for the 
fabrication of vaginal rings owing to their poor flexural and 
mechanical characteristics, a subset known as “thermoplastic 
elastomers” has been successfully applied to vaginal ring con-
struction. Most notably, ethylene vinyl acetate copolymers 
(PEVA) are used as both the drug matrix and the rate-limiting 
sheath in the combination (etonogestrel + ethinyl estradiol) 
contraceptive vaginal ring device Nuvaring®. A number of 
other subdermal, implantable drug-delivery devices are also 
fabricated from PEVA, including Implanon® and Virtasert®. 
The vinyl acetate content (typically ranging from approxi-
mately 10% to 40%) and the molecular weight characteristics 
of the PEVA material play a major role in determining the 
mechanical properties, the ease of processing, and the drug 
release rates of the finished drug-delivery device.
Nuvaring® is a nonbiodegradable, flexible, transparent, 
colorless, contraceptive vaginal ring (Table 1), developed 
by Organon Inc and first marketed in 2002. It contains two 
active compounds, progestin etonogestrel (11.7 mg) and 
estrogen ethinyl estradiol (2.7 mg), both located within a 
central PEVA (28% w/w vinyl acetate) core as a supersatu-
rated eutectic mixture, and surrounded by a nonmedicated 
polyethylene-co-vinyl acetate (9% w/w vinyl acetate) sheath 
layer. The slow permeation of the steroid molecules through 
the low-vinyl-acetate-content nonmedicated sheath provides 
for controlled release, resulting in mean daily release rates 
of 120 µg etonogestrel and 15 µg ethinyl estradiol over the 
3-week period of use. The ring is used continuously for 
3 weeks, and then removed for 1 week before being replaced 
with a new ring. Nuvaring® is highly efficacious, with a Pearl 
index of 1.18 and an efficacy of 99.1%. Off-label 28-day 
continuous use of Nuvaring® is also being evaluated.35
Despite the commercial success of Nuvaring®, there have 
been very few reports of the use of PEVA for microbicide-
 releasing vaginal rings, probably owing to ongoing dif-
ficulties in accessing clinical-grade materials for testing 
in humans. A comparison of the pharmacokinetics of the 
nonnucleoside reverse-transcriptase inhibitor UC781 in 
rabbits following vaginal administration of ring segments 
fabricated from PEVA, polyurethane, and silicone elastomer 
showed similar in vivo release rates and kinetics.8 Recently, a 
combination PEVA matrix-type ring providing simultaneous 
release of the microbicide candidate UC781 and the contra-
ceptive progestin levonorgestrel has been reported.36 If the 
proof of concept of a microbicide vaginal ring device can 
be realized with the dapivirine-releasing silicone elastomer 
ring, then these multipurpose prevention technologies that 
combine HIV protection with effective contraceptive regimes 
will be actively pursued.
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Table 2 Summary of microbicide-releasing vaginal ring devices either previously evaluated or under ongoing investigation
Microbicide(s) Polymer type Ring type References
Dapivirine Silicone elastomer 
Polyurethane 
Biosoluble acacia gum
Reservoir and matrix 
Matrix 
Reservoir
23,24,25 
6,7,9 
45
Maraviroc Silicone elastomer Matrix 34
CMPD167 Silicone elastomer Matrix 34
MC1220 Silicone elastomer Matrix 33
AZT Biosoluble acacia gum or a hydrogel Reservoir 44,45
Boc-LBA Biosoluble acacia gum Reservoir 45
Tenofovir Silicone elastomer (carrier) 
Polyurethane
Pod ring 
Matrix
38,40
MIV-160 Poly(ethylene-co-vinyl acetate) Matrix 58
UC781 Silicone elastomer 
Polyurethane 
Poly(ethylene-co-vinyl acetate)
Matrix 
Matrix 
Matrix
8 
8,37 
36
Dapivirine + tenofovir Biosoluble acacia gum or a hydrogel 
Polyurethane
Reservoir 
Matrix
45 
7
Dapivirine + maraviroc Silicone elastomer 
Poly(ethylene-co-vinyl acetate)
Matrix 
Matrix
n/a 
n/a
Tenofovir and acyclovir Silicone elastomer (carrier) Pod ring 38
IQP-0528 and tenofovir Polyurethane Matrix n/a
Saquinavir, lopinavir and ritonavir Silicone elastomer Matrix n/a
Abbreviations: n/a, reference not available; MRI, magnetic resonance imaging; PII, Phase II; C, control.
Thermoplastic polyurethanes are also being evaluated for 
use in microbicide-releasing vaginal rings. As with PEVA, 
the properties of polyurethanes can be readily tailored by 
controlling their chemical structure (Figure 2B), simply by 
adjusting the components of the reaction mixture (polymeric 
diol, a chain extender, and isocyanate) used in their synthesis. 
To date, polyurethane rings releasing either UC781, dapi-
virine, tenofovir, or a combination have been demonstrated in 
in vitro studies.6,7,9,37 Constant daily release of dapivirine from 
matrix-type ring prototypes was sustained over 30 days, with 
the release rate dependent on the initial drug-loading.6 Novel 
segmented polyurethane vaginal rings have also been evalu-
ated for simultaneous release of dapivirine and tenofovir. 
Each drug was incorporated into its own rod segment before 
joining the rods to prepare the intact ring device.7 While this 
approach permits independent formulation of the component 
microbicides and control of release rates, the complexity of 
design and the required scaled manufacturing are obstacles 
to further development.
New designs of vaginal ring  
for microbicide delivery
Several new designs of vaginal ring device are also in 
development, all seeking to overcome the drug-permeability 
constraints associated with release of hydrophilic and/or 
macromolecular actives from conventional silicone elastomer 
and thermoplastic systems.
The Versaring® technology platform (Auritec Pharma-
ceuticals) is based on drug-loaded pod inserts, comprising 
polymer-coated solid drug, incorporated into a silicone 
elastomer ring and exhibiting pseudo-zero order release 
kinetics.38–40 Drug cores are coated with layers of semiper-
meable poly(lactic acid) polymer. Coated drug pods are 
incorporated into silicone rings, and the drug is released 
through a delivery window in the silicone ring, with the 
release rate determined by the window diameter. The amount 
of drug released from each ring can be adjusted by changing 
the amount and composition of the polymer coating of the 
drug core, the size of the drug-delivery window, and the 
number of drug pods in each ring. Vaginal rings containing 
tenofovir provide in vitro daily release rates spanning 2.5 
orders of magnitude (10–4000 mcg/day for tenofovir). The 
modular nature of the rings permits the release of multiple 
drugs having very different physicochemical characteristics. 
To date, in vitro release of tenofovir and acyclovir from 
the same ring segments has been demonstrated.40 In vivo 
studies have demonstrated sustained release of tenofovir in 
the micro-molar range over 14 days in rabbits and 28 days 
in macaques, with no local inflammation or altered vaginal 
flora.40 In rabbits, the vaginal tissue tenofovir levels at 
sacrifice were 3597 ± 1678 ng/g. In the macaques, vaginal 
biopsies proximal and distal to the inserted rings at days 7 
and 21 measured tenofovir levels at 76 ± 54 mcg/g, over 100 
times the IC 50 of tenofovir (2 µM). The data demonstrates 
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the feasibility of a 1-month tenofovir microbicide ring for 
women.
Similar to the pod-insert vaginal ring, rod and tablet-insert 
vaginal rings comprise one or more polymeric solid dosage 
forms (lyophilized polymer gel rods and directly compressed 
tablets, respectively) inserted into a silicone elastomer ring.41 
While the ring acts primarily as a retainer for the solid dosage 
inserts, it may also be used to load and deliver other micro-
bicide candidates compatible with conventional permeation-
controlled release mechanisms. Lyophilized inserts may be 
prepared by freeze-drying microbicide-loaded aqueous gel 
formulations. This technology is potentially useful for the 
production of solid dosage inserts containing peptide- and 
protein-based microbicide candidates, since it does not involve 
high temperatures, and the water-free insert serves to stabilize 
the active biomolecule. Once administered, the gel is slowly 
reconstituted by imbibing vaginal fluid, leading to sustained 
release of the active agent. Similar lyophilized tablets have 
recently been reported for the formulation of dapivirine.42 
The compressed tablet-insert strategy makes use of traditional 
direct-compression tableting technology to manufacture con-
ventional sustained-release solid dosage forms.
Given the regulatory constraints, very few polymer 
materials apart from silicone elastomer and PEVA have 
been considered, to date, for the fabrication of vaginal rings. 
Matrix-type rings constructed from styrene-butadiene block 
copolymers have previously been evaluated for the sustained 
release of 17β-estradiol for the treatment of postmenopausal 
symptoms.43 The use of polymers that control drug release 
by mechanisms other than permeation might be useful for 
the delivery of hydrophilic and/or large molecular weight 
actives. Vaginal rings constructed from biosoluble acacia 
gum, a nonbiodegradable hydrogel of 2-hydroxyethyl meth-
acrylate, and sodium methacrylate, designed to provide 
sustained release for up to 28 days, have been reported for 
the simultaneous release of combination antiretroviral HIV 
microbicides and for combinations of microbicides with 
nonhormonal contraceptives.44,45
A microbicide-releasing diaphragm
The SILCS diaphragm has been under development by the 
Program for Appropriate Technology in Health since 1994 
as an advanced, single-sized, cervical-barrier contraceptive 
device (Figure 5).46–51 Similar in format to a reservoir-type 
A
B
C
SILCS
diaphragm
Spring core
with spacers
Spring core
Direction arrow
Removal dome
Cervical rim
Removal rim
Grip dimples Cervical cup
D
E
Figure 5 The SILCS diaphragm. (A) The thermoplastic spring core consists of nylon-6 in the original SILCS device and polyoxymethylene in the dapivirine-releasing device. 
(B) Spring core with over-molded silicone elastomer spacers, for positioning the spring core within the injection molds during the final overmolding step. (C) Finished 
diaphragm device, formed by overmolding the spring core + spacers with silicone elastomer. (D) Design features of the SILCS diaphragm. (E) Photograph of the SILCS 
diaphragm.
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vaginal ring device, SILCS contains a specially designed 
flexible polymeric spring core (made from nylon-6), which 
is over-molded with silicone elastomer to form the barrier 
sheath. In preliminary clinical studies, SILCS was found to 
be safe; and it performed as well as the standard latex dia-
phragm in preventing sperm from reaching the cervix when 
both devices were used with the spermicide nonoxynol-9. The 
contraceptive efficacy of SILCS is currently being evaluated 
in combination use with the contraceptive gel BufferGel®. 
If protection is similar to the standard diaphragm, these data 
will provide the basis for an application to the US Food and 
Drug Administration.
Given the similarity of structure between the nonmedi-
cated SILCS device and a reservoir-type, drug-releasing 
vaginal ring (ie, both contain a central polymeric core and 
an over-molded polymer sheath), and the newly emerging 
emphasis on the development of multipurpose prevention 
strategies,52–54 the incorporation of a microbicide delivery 
function into SILCS is currently being actively pursued.55 
A modified SILCS device comprising an injection-molded 
polyoxymethylene spring core, loaded with up to 20% dapi-
virine and over-molded with the standard silicone elastomer 
material, has been shown to provide constant in vitro daily 
release rates during continuous testing over 6 months.56
Manufacturing and scale-up
The general methods for the manufacture of silicone 
elastomer and thermoplastic vaginal rings, outlined in 
Figures 6 and 7 respectively, involve the incorporation of the 
solid drug active(s) into the polymer, followed by injection-
molding or extrusion into precision-machined ring-holds to 
Silicone elastomer base
components
Silicone elastomer active mix
components
Add solid drug (s)
and mix
Part A Part B
Mix
Injection
molding
Silicone elastomer active mix
Drug-loaded
vaginal ring
Figure 6 General manufacturing method for fabricating drug-loaded silicone 
elastomer matrix rings. More complex methods are required for advanced ring 
designs.
form the final device. Depending on the format and complex-
ity of the ring product design, there may be several distinct 
steps in the manufacturing process. Although the polymer-
processing techniques of injection molding and extrusion 
are ubiquitous in the manufacturing of plastic parts for a 
wide variety of everyday applications (including various 
medical devices), the availability of contract manufacturers 
capable of handling the regulatory issues, manufacturing 
complexities, and raw material supplies associated with 
drug-delivery devices is very limited. These issues have 
been discussed previously,57 and are particularly pertinent, 
given the progress of the 25 mg dapivirine ring to Phase III 
clinical testing. If the MTN 020 trial (Table 1) successfully 
demonstrates the efficacy of the 25 mg dapivirine matrix 
ring in reducing the incidence of HIV transmission, then 
several hurdles will need to be overcome before commercial 
launch, including accurate projected forecast demand and 
significant expansion of manufacturing capacity to meet 
global needs.
Mix drug and pellets
Thermoplastic pellets
(as supplied)
Solid drug substance
(may be micronised)
Drug-loaded
thermoplastic pellets
Injection molding or
hot melt extrusion
Drug-loaded
vaginal ring
Mix and extrude in a
twin screw extruder
Figure 7 General manufacturing method for the fabrication of drug-loaded 
thermoplastic matrix rings. More complex methods are required for advanced ring 
designs.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
603
Vaginal rings for HIV microbicides
International Journal of Women’s Health 2012:4
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Folkman J, Long DM Jr, Rosenbaum R. Silicone rubber: a new diffu-
sion property useful for general anesthesia. Science. 1966;154(3745): 
148–149.
 2. Folkman J, Long DM. The use of silicone rubber as a carrier for pro-
longed drug therapy. J Surg Res. 1964;4(3):139–142.
 3. Dziuk PJ, Cook B. Passage of steroids through silicone rubber. 
 Endocrinology. 1966;78(1):208–211.
 4. Duncan GW, inventor; The Upjohn Company, assignee. Medicated 
devices and methods. United States patent US 3545439. December 8, 
1970.
 5. Hoffman AS. The origins and evolution of “controlled” drug delivery 
systems. J Control Release. 2008;132(3):153–163.
 6. Gupta KM, Pearce SM, Poursaid AE, et al. Polyurethane intravaginal 
ring for controlled delivery of dapivirine, a nonnucleoside reverse tran-
scriptase inhibitor of HIV-1. J Pharm Sci. 2008;97(10):4228–4239.
 7. Johnson T, Gupta K, Fabian J, Albright T, Kiser P. Segmented 
polyurethane intravaginal rings for the sustained combined delivery 
of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci. 
2010;39(4):203–212.
 8. Clark MR, Kiser PF, Loxley A, McConville C, Malcolm RK, Friend DR. 
Pharmacokinetics of UC781-loaded intravaginal ring segments in 
rabbits: a comparison of polymer matrices. Drug Deliv Transl Res. 
2011;1(3):238–246.
 9. Kaur M, Gupta KM, Poursaid AE, et al. Engineering a degradable 
polyurethane intravaginal ring for sustained delivery of dapivirine. 
Drug Delivery Trans Res. 2011;1(3):223–237.
 10. Colas A, Curtis J. Silicone biomaterials: history and chemistry. In: 
Biomaterials Science: An Introduction to Materials in Medicine. 2nd ed. 
Elsevier Academic Press; 2004:80–85.
 11. Curtis J, Colas A. Medical applications of silicones. In: Ratner BD, 
Hoffman AS, Schoen FJ, Lemons JE, editors. Biomaterials Science: 
An Introduction to Materials in Medicine. 2nd ed. Elsevier Academic 
Press; 2004:698–707.
 12. Al-Azzawi F, Buckler HM; for the United Kingdom Vaginal Ring 
Investigator Group. Comparison of a novel vaginal ring delivering 
estradiol acetate versus oral estradiol for relief of vasomotor menopausal 
symptoms. Climacteric. 2003;6(2):118–127.
 13. Barentsen R, vandeWeijer PHM, Schram JHN. Continuous low 
dose estradiol released from a vaginal ring versus estriol vaginal 
cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol. 
1997;71(1):73–80.
 14. Buckler H, Al-Azzawi F; for the UK VR Multicentre Trial Group. 
The effect of a novel vaginal ring delivering oestradiol acetate on cli-
macteric symptoms in postmenopausal women. Brit J Obstet Gynecol. 
2003;110(8):753–759.
 15. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring 
for relief of menopausal symptoms. Obstet Gynecol. 2003;102(4): 
823–834.
 16. Croxatto HB, Brache V, Massai R, et al. Feasibility study of Nestorone-
ethinylestradiol vaginal contraceptive ring for emergency contraception. 
Contraception. 2006;73(1):46–52.
 17. Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a 
unique pharmacological profile. Steroids. 2000;65(10–11):629–636.
 18. Fraser IS, Weisberg E, Brache V, et al. Serum Nestorone and ethinyl 
estradiol levels, and ovulation inhibition in women using three different 
dosage combinations of a Nestorone progestogen-ethinyl estradiol con-
traceptive vaginal ring on a bleeding-signaled regimen.  Contraception. 
2005;72(1):40–45.
 19. Sivin I, Mishell DR Jr, Alvarez F, et al. Contraceptive vaginal rings 
releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. 
Contraception. 2005;71(2):122–129.
 20. Malcolm K, Woolfson D, Russell J, Andrews C. In vitro release of 
nonoxynol-9 from silicone matrix intravaginal rings. J Control Release. 
2003;91(3):355–364.
 21. Van Damme L, Ramgee G, Alvary M, et al. Effectiveness of COL-
1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female 
sex workers: a randomised controlled trial. Lancet. 2002;360(9338): 
971–977.
 22. Roddy RE, Zekeng L, Ryan K, et al. A controlled trial of nonoxynol 
9 film to reduce male-to-female transmission of sexually transmitted 
diseases. N Engl J Med. 1998;339:504–510.
 23. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled 
release of the HIV microbicide TMC120 from silicone elastomer vaginal 
rings. J Antimicrob Chemother. 2005;56(5):954–956.
 24. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z. 
Safety and availability of dapivirine (TMC120) delivered from an 
intravaginal ring. AIDS Res Hum Retroviruses. 2009;25(5):483–488.
 25. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of 
dapivirine delivery from matrix and reservoir intravaginal rings to HIV-
 negative women. J Acquir Immune Defic Syndr. 2009;51(4):416–423.
 26. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal trans-
mission of HIV-1 in hu-SCID mice by the non-nucleoside reverse tran-
scriptase inhibitor TMC120 in a gel formulation. AIDS. 2003;17(11): 
1597–1604.
 27. Herrewege YV, Michiels J, Van Roey J, et al. In vitro evaluation of 
nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-
R147681 as human immunodeficiency virus microbicides. Antimicrob 
Agents Chemother. 2004;48(1):337–339.
 28. Woolfson AD, Elliott GR, Gilligan CA, Passmore CM. Design of an 
intravaginal ring for the controlled delivery of 17 beta-estradiol as its 
3-acetate ester. J Control Release. 1999;61(3):319–328.
 29. Woolfson AD, Malcolm RK, Gallagher RJ. Design of a silicone reser-
voir intravaginal ring for the delivery of oxybutynin. J Control Release. 
2003;91(3):465–476.
 30. Woolfson AD, Malcolm RK, Gorman SP, Jones DS, Brown AF, 
McCullagh SD. Self-lubricating silicone elastomer biomaterials. 
J Mater Chem. 2003;13(10):2465–2470.
 31. Malcolm RK, McCullagh SD, Woolfson AD, Gorman SP, Jones DS, 
Cuddy J. Controlled release of a model antibacterial drug from a novel 
self-lubricating silicone biomaterial. J Control Release. 2004;97(2): 
313–320.
 32. Promadej-Lanier N, Smith J, Srinivasan P, et al. Development and evalu-
ation of a vaginal ring device for sustained delivery of HIV microbicides 
to non-human primates. J Med Primatol. 2009;38(4):263–271.
 33. Fetherston S, Geer L, Veazey RS, et al. Partial protection against mul-
tiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone 
elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob 
Chemother. In press.
 34. Malcolm RK, Veazey RS, Geer L, et al. Sustained release of the 
CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus 
macaques. Antimicrob Agents Chemother. 2012;56(5):2252–2258.
 35. Sulak PJ, Smith V, Coffee A, et al. Frequency and management 
of breakthrough bleeding with continuous use of the transvaginal 
contraceptive ring: a randomized controlled trial. Obstets Gynecol. 
2008;112(3):563–571.
 36. Loxley A, Mitchnick M, Okoh O, et al. Ethylene vinyl acetate intrav-
aginal rings for the simultaneous delivery of the antiretroviral UC781 
and contraceptive levonorgestrel. Drug Delivery Trans Res. 2011;1(3): 
247–255.
 37. Clark MR, Johnson TJ, McCabe RT, et al. A hot-melt extruded intrav-
aginal ring for the sustained delivery of the antiretroviral microbicide 
UC781. J Pharm Sci. 2012;101(2):576–587.
 38. Baum MM, Butkyavichene I, Gilman J, et al. An intravaginal ring for 
the simultaneous delivery of multiple drugs. J Pharm Sci. 2012;101(8): 
2833–2843.
 39. Keller MJ, Malone AM, Carpenter CA, et al. Safety and pharmacokinet-
ics of aciclovir in women following release from a silicone elastomer 
vaginal ring. J Antimicrob Chemother. 2012;67(8):2005–2012.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
604
Malcolm et al
International Journal of Women’s Health
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-womens-health-journal
The International Journal of Women’s Health is an international, peer-
reviewed open-access journal publishing original research, reports, 
editorials, reviews and commentaries on all aspects of women’s 
healthcare including gynecology, obstetrics, and breast cancer. The 
manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
International Journal of Women’s Health 2012:4
 40. Moss JA, Malone AM, Smith TJ, et al. Simultaneous delivery of 
tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents 
Chemother. 2012;56(2):875–882.
 41. Morrow RJ, Woolfson AD, Donnelly L, et al. Sustained release of 
proteins from a modified vaginal ring device. Eur J Pharm Biopharm. 
2011;77(1):3–10.
 42. Woolfson AD, Umrethia ML, Kett VL, et al. Freeze-dried, mucoadhe-
sive system for vaginal delivery of the HIV microbicide, dapivirine: 
optimisation by an artificial neural network. Int J Pharm. 2010;388: 
136–143.
 43. Vartiainen J, Wahlström T, Nilsson CG. Effects and acceptability of 
a new 17 beta-oestradiol-releasing vaginal ring in the treatment of 
postmenopausal complaints. Maturitas. 1993;17(2):129–137.
 44. Han YA, Singh M, Saxena BB. Development of vaginal rings for 
sustained release of nonhormonal contraceptives and anti-HIV agents. 
Contraception. 2007;76(2):132–138.
 45. Saxena B, Han Y, Fu D, et al. Sustained release of microbicides by 
newly engineered vaginal rings. AIDS. 2009;23(8):917–922.
 46. Yang CC, Maravilla KR, Kilbourne-Brook M, Austin G. Magnetic 
resonance imaging of SILCS diaphragm: anatomical considerations and 
corroboration with clinical fit. Contraception. 2007;76(3):238–244.
 47. Coffey PS, Kilbourne-Brook M, Brache V, Cochón L. Comparative 
acceptability of the SILCS and Ortho ALL-FLEX® diaphragms among 
couples in the Dominican Republic. Contraception. 2008;78(5): 
418–423.
 48. Coffey PS, Kilbourne-Brook M. Wear and care of the SILCS diaphragm: 
experience from three countries. Sex Health. 2010;7(2):159–164.
 49. Coffey PS, Kilbourne-Brook M, Beksinska M, Thongkrajai E. 
Short-term acceptability of a single-size diaphragm among couples 
in South Africa and Thailand. J Fam Plann Reprod Health Care. 
2008;34(4):233–236.
 50. Schwartz JL, Ballagh SA, Creinin MD, et al. SILCS diaphragm: post-
coital testing of a new single-size contraceptive device. Contraception. 
2008;78(3):237–244.
 51. Moench TR, Chipato T, Padian NS. Preventing disease by protecting 
the cervix: the unexplored promise of internal vaginal barrier devices. 
AIDS. 2001;15(13):1595–1602.
 52. Friend D. Intravaginal rings: controlled release systems for contracep-
tion and prevention of transmission of sexually transmitted infections. 
Drug Deliv Transl Res. 2011;1(3):185–193.
 53. Friend D, Doncel G. Combining prevention of HIV-1, other sexually 
transmitted infections and unintended pregnancies: development 
of dual-protection technologies. Antiviral Res. 2010;88 Suppl 1: 
S47–S54.
 54. Thurman AR, Clark MR, Doncel GF. Multipurpose prevention 
 technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended 
pregnancies. Infect Dis Obstet Gynecol. Epub 2011 Aug 9.
 55. Major I, Lowry D, Malcolm K, et al. Development of a microbicide-
releasing diaphragm as an HIV prevention strategy. Conf Proc IEEE 
Eng Biol Soc. 2010:1089–1092.
 56. Major I, Boyd P, Kilbourne-Brook M, et al. A modified SILCS 
contraceptive diaphragm for long-term controlled release of the HIV 
microbicide dapivirine. Contraception. In press.
 57. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances 
in microbicide vaginal rings. Antiviral Res. 2010;88 Suppl 1: 
S30–S39.
 58. Aravantinou M, Singer R, Derby N, et al. The nonnucleoside reverse 
transcription inhibitor MIV-160 delivered from an intravaginal ring, 
but not from a carrageenan gel, protects against simian/human immu-
nodeficiency virus-RT infection. AIDS Res Human Retrovir. 2012. 
In press.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
605
Vaginal rings for HIV microbicides
